Turing Pharmaceuticals completes $90 million Series A financing

Turing Pharmaceuticals AG, a privately-held biopharmaceutical company focused on discovering and developing treatments for serious and life-threatening diseases, today announced the completion of its Series A financing. The $90 million round was led by Martin Shkreli, Founder & Chief Executive Officer. One of the largest Series A rounds in biotech history, the financing included participation from multiple preeminent institutional equity investors and the simultaneous issuance of senior secured debt.

The company intends to invest the proceeds from the Series A financing in acquisitions as well as advancing and accelerating its growing pipeline of novel drug candidates.

"We are very happy with the institutional interest in our first capital raise. It's a great reflection on our business model and the collective track record of our leadership team developing breakthrough treatments for serious diseases," Mr. Shkreli said. "We plan to accelerate clinical trials for several treatments and are pleased to announce an immediate addition to our portfolio," he added. "We look forward to the continued execution of our plan to bring new treatments for serious diseases to patients, helping us maximize shareholder value."

SOURCE Turing Pharmaceuticals AG

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Albumedix announces recombinant human albumin supply partnership with FUJIFILM Wako Pure Chemical Corporation for the Japanese, Chinese and Hong Kong markets